Vanguard Group Inc Viracta Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.57 Trillion
  • Q4 2024

A detailed history of Vanguard Group Inc transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 289,174 shares of VIRX stock, worth $8,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares
289,174
Previous 954,485 69.7%
Holding current value
$8,675
Previous $219,000 79.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$0.14 - $0.26 $93,143 - $172,980
-665,311 Reduced 69.7%
289,174 $46,000
Q3 2024

Nov 13, 2024
SELL
$0.21 - $0.56 $43,426 - $115,805
-206,795 Reduced 17.81%
954,485 $219,000
Q4 2023

Feb 14, 2024
BUY
$0.44 - $1.04 $5,881 - $13,902
13,368 Added 1.16%
1,161,280 $661,000
Q4 2022

Feb 10, 2023
BUY
$1.26 - $4.38 $42,265 - $146,922
33,544 Added 3.01%
1,147,912 $1.68 Million
Q3 2022

Nov 14, 2022
BUY
$3.32 - $5.69 $687,598 - $1.18 Million
207,108 Added 22.83%
1,114,368 $4.76 Million
Q2 2022

Aug 12, 2022
BUY
$1.87 - $5.0 $146,576 - $391,915
78,383 Added 9.46%
907,260 $3.52 Million
Q1 2022

May 13, 2022
SELL
$2.23 - $4.76 $1.39 Million - $2.98 Million
-625,449 Reduced 43.01%
828,877 $3.95 Million
Q4 2021

Feb 14, 2022
BUY
$3.37 - $7.91 $32,726 - $76,814
9,711 Added 0.67%
1,454,326 $5.31 Million
Q3 2021

Nov 12, 2021
BUY
$7.84 - $12.53 $83,833 - $133,983
10,693 Added 0.75%
1,444,615 $11.6 Million
Q2 2021

Aug 13, 2021
BUY
$7.55 - $12.95 $10.8 Million - $18.6 Million
1,433,922 New
1,433,922 $16.3 Million

Others Institutions Holding VIRX

# of Institutions
37
Shares Held
3.66M
Call Options Held
1.8K
Put Options Held
0
View Full List

About Viracta Therapeutics, Inc.

VIRX Quotes by TradingView
  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $1.13M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email